CDCP2 Inhibitors
CDCP2 inhibitors encompass a group of chemical compounds that can attenuate the functional activity of CDCP2 through the modulation of various signaling pathways that CDCP2 is involved in. For instance, kinase inhibitors like Staurosporine and Bisindolylmaleimide I significantly reduce the kinase-driven phosphorylation of CDCP2, a post-translational modification that is critical for its role in cell adhesion and migration. LY 294002 and Wortmannin, as PI3K inhibitors, prevent the formation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which is essential for the activation of downstream pathways involving CDCP2, thus diminishing its influence on cellular survival and proliferation. Similarly, the Src family kinase inhibitor PP 2, and Dasatinib, a broad-spectrum tyrosine kinase inhibitor, impair the phosphorylation of CDCP2, which is necessary for its mediation in mechanisms such as cell migration.
Further impacting the CDCP2 signaling cascade are U0126 and PD 98059, both targeting the MEK1/2 pathway, which is potentially implicated in CDCP2-modulated signaling processes, and SP600125, an inhibitor of JNK that can reduce CDCP2's role in apoptosis and differentiation. SB 203580's inhibition of p38 MAPK, and Rapamycin's targeting of mTOR, both contribute to the attenuation of CDCP2's involvement in stress responses and cell survival, respectively. Moreover, Y-27632 inhibits Rho-associated kinase (ROCK), which has implications for CDCP2's influence on cell motility and proliferation. Collectively, these compounds, through their targeted effects on specific kinases and signaling molecules, effectively diminish the functional activity of CDCP2. Each inhibitor works by disrupting a particular signaling pathway or kinase activity necessary for the full expression of CDCP2's biological roles.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that by inhibiting a broad spectrum of protein kinases, can diminish the phosphorylation state of CDCP2, potentially reducing its activity in signal transduction related to cell adhesion and migration. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
A specific inhibitor of Protein Kinase C (PKC), which could decrease the phosphorylation and activation of CDCP2 as PKC can directly phosphorylate substrates like CDCP2 influencing cell motility and proliferation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphoinositide 3-kinases (PI3K) inhibitor that may reduce CDCP2-mediated signaling by preventing the formation of PIP3, which is crucial for CDCP2's role in survival and growth pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
An irreversible inhibitor of PI3K, leading to a reduction in the activation of downstream targets including CDCP2, which relies on PI3K signaling for its cellular functions. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
A Src family kinase inhibitor that would result in diminished CDCP2 activity, given that Src family kinases can phosphorylate and modulate CDCP2 function in processes such as cell migration. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A tyrosine kinase inhibitor with the potential to reduce CDCP2 activity by inhibiting Src family kinases, which are known to phosphorylate CDCP2 and regulate its function in cell signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An MEK inhibitor that can indirectly decrease CDCP2's role in signaling pathways by preventing the activation of ERK1/2, which could be involved in CDCP2-mediated signaling processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that could diminish CDCP2's functional involvement in the stress response and apoptosis pathways in which p38 MAPK may influence CDCP2 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that could lead to a decrease in CDCP2's role in cell growth and survival pathways, as mTOR signaling is crucial for the functions associated with CDCP2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A non-competitive inhibitor of MEK1/2 which could reduce CDCP2 signaling activities by blocking the activation of the MAPK/ERK pathway, a potential modulator of CDCP2's function. | ||||||